Neuroone Medical Technologies (NMTC) Common Equity (2010 - 2026)

Neuroone Medical Technologies (NMTC) has reported Common Equity for 17 consecutive years, with $3.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity fell 53.93% year-over-year to $3.8 million; the trailing twelve-month figure through Jun 2026 stood at $3.8 million (down 53.93% YoY), and the FY2025 full-year result was $7.1 million, up 760.39% from the prior year.
• Common Equity eased to $3.8 million in Q2 2026 per NMTC's latest filing, from $5.1 million in the prior quarter.
• Across five years, Common Equity topped out at $13.1 million in Q1 2022 and bottomed at $822013.0 in Q3 2024.
• Historically, Common Equity has averaged $5.8 million across 5 years, with a median of $5.3 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Common Equity sank 86.85% in 2024, then surged 760.39% in 2025.
• Over 5 years, Common Equity stood at $8.2 million in 2022, then tumbled by 45.93% to $4.4 million in 2023, then slumped by 33.56% to $2.9 million in 2024, then jumped by 118.1% to $6.4 million in 2025, then slumped by 41.15% to $3.8 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $3.8 million, $5.1 million, and $6.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.